The function, mechanisms, and role of the genes PTEN and TP53 and the effects of asbestos in the development of malignant mesothelioma: A review focused on the genes' molecular mechanisms

Tumor Biology

Volumn 35, Issue 2, 2014, Pages 889-901

  De Assis, Leonardo Vinícius Monteiro ^a   Isoldi, Mauro César ^a  

^a FEDERAL UNIVERSITY OF OURO PRETO   (Brazil)

Author keywords

Asbestos; Mesothelioma; p53; PI3K AKT; PTEN; Quasi sufficiency and haploinsufficiency genes

Indexed keywords

ALKYLATING AGENT; ASBESTOS; BEVACIZUMAB; CISPLATIN; ERLOTINIB; EVEROLIMUS; FOLIC ACID ANTAGONIST; GEFITINIB; MAMMALIAN TARGET OF RAPAMYCIN; PEMETREXED; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PLATINUM DERIVATIVE; PROTEIN KINASE B INHIBITOR; PROTEIN P53; RAPAMYCIN; TEMSIROLIMUS;

CANCER CHEMOTHERAPY; CELL NUCLEUS; GENE FUNCTION; GENE THERAPY; HAPLOINSUFFICIENCY; HUMAN; KIDNEY CARCINOMA; LUNG NON SMALL CELL CANCER; MALIGNANT MESOTHELIOMA; MANTLE CELL LYMPHOMA; MOLECULAR GENETICS; MOLECULAR MECHANICS; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SENESCENCE;

ASBESTOS; CARCINOGENS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; MEMBRANE PROTEINS; MESOTHELIOMA; PTEN PHOSPHOHYDROLASE; SIMIAN VIRUS 40; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84898877536     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-013-1210-4     Document Type: Review

References (122)

1. Mott FE. Mesothelioma: a review. Ochsner J. 2012;12(1):70-9. doi:10.1043/1524-5012-12.1.70.
2. Fennell DA. Genetics and molecular biology of mesothelioma. Recent Results Cancer Res. 2011;189:149-67. doi:10.1007/978-3-642-10862-4-9.
3. van Meerbeeck JP, Gaafar R, Manegold C, Van Klaveren RJ, Van Marck EA, Vincent M, et al. Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol. 2005;23(28):6881-9.
4. Tan C, Treasure T. Mesothelioma: time to take stock. J R Soc Med. 2005;98(10):455-8. doi:10.1258/jrsm.98.10.455.
5. ATSDR. Public health statement - asbestos. Atlanta: Agency for Toxic and Disease Registry; 2001.
6. Yang H, Testa J, Carbone M. Mesothelioma epidemiology, carcinogenesis, and pathogenesis. Curr Treat Options in Oncol. 2008;9(2-3):147-57. doi:10.1007/s11864-008-0067-z.
7. Eom M, Abdul-Ghafar J, Park SMHJ, Hong SW, Kwon KY, Ko ES, et al. No detection of simian virus 40 in malignant mesothelioma in Korea. Korean J Pathol. 2013;47(2):124-9.
8. Qi F, Carbone M, Yang H, Gaudino G. Simian virus 40 transformation, malignant mesothelioma and brain tumors. Expert Rev Respir Med. 2013;5(5):683-97. doi:10.1586/ers.11.51.
9. Jasani B, Gibbs A. Mesothelioma not associated with asbestos exposure. Arch Pathol Lab Med. 2012;136(3):262-7. doi:10.5858/arpa.2011-0039-RA.
10. Kroczynska B, Cutrone R, Bocchetta M, Yang H, Elmishad AG, Vacek P, et al. Crocidolite asbestos and SV40 are cocarcinogens in human mesothelial cells and in causing mesothelioma in hamsters. Proc Natl Acad Sci. 2006;103(38):14128-33. doi:10.1073/pnas.0604544103.
11. Manfredi JJ, Dong J, Liu W-J, Resnick-Silverman L, Qiao R, Chahinian P, et al. Evidence against a role for SV40 in human mesothelioma. Cancer Res. 2005;65(7):2602-9.
12. Jaurand M-C, Fleury-Feith J. Pathogenesis of malignant pleural mesothelioma. Respirology. 2005;10(1):2-8. doi:10.1111/j.1440-1843.2005.00694.x.
13. Jean D, Daubriac J, Le Pimpec-Barthes F, Galateau-Salle F, Jaurand M-C. Molecular changes in mesothelioma with an impact on prognosis and treatment. Arch Pathol Lab Med. 2012;136(3):277-93. doi:10.5858/arpa.2011-0215-RA.
14. Hu Q, Akatsuka S, Yamashita Y, Ohara H, Nagai H, Okazaki Y, et al. Homozygous deletion of CDKN2A/2B is a hallmark of iron-induced high-grade rat mesothelioma. Lab Investig. 2010;90(3):360-73.
15. Ladanyi M. Implications of P16/CDKN2A deletion in pleural mesotheliomas. Lung Cancer. 2005;49(Supplement 1(0)):S95-S8. doi:10.1016/j.lungcan.2005.03.017.
16. Sekido Y, Pass HI, Bader S, Mew DJY, Christman MF, Gazdar AF, et al. Neurofibromatosis Type 2 (NF2) gene is somatically mutated in mesothelioma but not in lung cancer. Cancer Res. 1995;55(6):1227-31.
17. Li W, You L, Cooper J, Schiavon G, Pepe-Caprio A, Zhou L, et al. Merlin/NF2 suppresses tumorigenesis by inhibiting the E3 ubiquitin ligase CRL4DCAF1 in the nucleus. Cell. 2010;140(4):477-90. doi:10.1016/j.cell.2010.01. 029.
18. Suzuki Y, Murakami H, Kawaguchi K, Tanigushi T, Fujii M, Shinjo K, et al. Activation of the PI3K-AKT pathway in human malignant mesothelioma cells. Mol Med Rep. 2009;2(2):181-8.
19. Altomare DA, You H, Xiao GH, Ramos-Nino ME, Skele KL, De Rienzo A, et al. Human and mouse mesotheliomas exhibit elevated AKT/PKB activity, which can be targeted pharmacologically to inhibit tumor cell growth. Oncogene. 2005;24(40):6080-9. doi:10.1038/sj.onc.1208744.
20. Maehama T, Dixon JE. The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem. 1998;273(22):13375-8. doi:10.1074/jbc.273.22.13375.
21. Wilson SM, Barbone D, Yang T-M, Jablons DM, Bueno R, Sugarbaker DJ, et al. mTOR mediates survival signals in malignant mesothelioma grown as tumor fragment spheroids. Am J Respir Cell Mol Biol. 2008;39(5):576-83. doi:10.1165/rcmb.2007-0460OC.
22. Agarwal V, Campbell A, Beaumont K, Cawkwell L, Lind M. PTEN protein expression in malignant pleural mesothelioma. Tumor Biol. 2012;34(2):847-51. doi:10.1007/s13277-012-0615-9.
23. Opitz I, Soltermann A, Abaecherli M, Hinterberger M, Probst-Hensch N, Stahel R, et al. PTEN expression is a strong predictor of survival in mesothelioma patients. Eur J Cardiothorac Surg. 2008;33(3):501-5. doi:10.1016/j.ejcts.2007.09.045.
24. Frezza C, Martins CP. From tumor prevention to therapy: empowering p53 to fight back. Drug Resist Updat. 2012;15(5):258-67. Reviews and commentaries in antimicrobial and anticancer chemotherapy.
25. Kafiri G, Thomas DM, Shepherd NA, Krausz T, Lane DP, Hall PA. p53 expression is common in malignant mesothelioma. Histopathology. 1992;21(4):331-4. doi:10.1111/j.1365-2559.1992.tb00403.x.
26. Freeman DJ, Li AG, Wei G, Li H-H, Kertesz N, Lesche R, et al. PTEN tumor suppressor regulates p53 protein levels and activity through phosphatase-dependent and -independent mechanisms. Cancer Cell. 2003;3(2):117-30. doi:10.1016/S1535-6108(03)00021-7.
27. Salmena L, Carracedo A, Pandolfi PP. Tenets of PTEN tumor suppression. Cell. 2008;133(3):403-14.
28. Heyn H, Carmona FJ, Gomez A, Ferreira HJ, Bell JT, Sayols S, et al. DNA methylation profiling in breast cancer discordant identical twins identifies DOK7 as novel epigenetic biomarker. Carcinogenesis. 2013;34(1):102-8. doi:10.1093/carcin/bgs321.
29. Das PM, Singal R. DNA methylation and cancer. J Clin Oncol. 2004;22(22):4632-42. doi:10.1200/jco.2004.07.151.
30. Esteller M, Corn PG, Baylin SB, Herman JG. A gene hypermethylation profile of human cancer. Cancer Res. 2001;61(8):3225-9.
31. Goto Y, Shinjo K, Kondo Y, Shen L, Toyota M, Suzuki H, et al. Epigenetic profiles distinguish malignant pleural mesothelioma from lung adenocarcinoma. Cancer Res. 2009;69(23):9073-82. doi:10.1158/0008-5472.can-09-1595.
32. Hama R, Watanabe Y, Shinada K, Yamada Y, Ogata Y, Yoshida Y, et al. Characterization of DNA hypermethylation in two cases of peritoneal mesothelioma. Tumor Biol. 2012;33(6):2031-40. doi:10.1007/s13277-012-0462-8.
33. LaDou J. The asbestos cancer epidemic. Environ Health Perspect. 2004;112(3):285-90. doi:10.2307/3435648.
34. McDonald AD, McDonald JC. Mesothelioma after crocidolite exposure during gas mask manufacture. Environ Res. 1978;17(3):340-6. doi:10.1016/0013-9351(78) 90038-5.
35. Hansen J, de Klerk NH, Musk AW, Hobbs MS. Environmental exposure to crocidolite and mesothelioma: exposure-response relationships. Am J Respir Crit Care Med. 1998;157(1):69-75.
36. Luo S, Liu X, Mu S, Tsai SP, Wen CP. Asbestos related diseases from environmental exposure to crocidolite in Da-yao, China. I. Review of exposure and epidemiological data. Occup Environ Med. 2003;60(1):35-42. doi:10.1136/oem.60.1.35.
37. Powers A, Carbone M. The role of environmental carcinogens, viruses and genetic predisposition in the pathogenesis of mesothelioma. Cancer Biol Ther. 2002;1(4):348-53.
38. INCA: INdC-. Amianto http://www.inca.gov.br/conteudo-view.asp?ID=15 (2013). Accessed 25 Jan 2013.
39. Pedra F, Tambellini AT, Pereira BB, Carioca da Costa AC, Albuquerque de Castro H. Mesothelioma mortality in Brazil, 1980-2003. Int J Occup Environ Health. 2008;14(3):170-5.
40. Roggli VL, Oury TD, Moffat EJ. Malignant mesothelioma in women. Anat Pathol. 1997;2:147-63.
41. Price B, Ware A. Mesothelioma trends in the United States: an update based on surveillance, epidemiology, and end results program data for 1973 through 2003. Am J Epidemiol. 2004;159(2):107-12. doi:10.1093/aje/kwh025.
42. Mesothelioma incidence statistics: Cancer Research Center. http://www.cancerresearchuk.org/cancer-info/cancerstats/types/Mesothelioma/ incidence/incidence (2012). Accessed 9 Jan 2013
43. Magnani C, Agudo A, Gonzalez CA, Andrion A, Calleja A, Chellini E, et al. Multicentric study on malignant pleural mesothelioma and non-occupational exposure to asbestos. Br J Cancer. 2000;83(1):104-11.
44. Yang H, Bocchetta M, Kroczynska B, Elmishad AG, Chen Y, Liu Z, et al. TNF-α inhibits asbestos-induced cytotoxicity via a NF-κB-dependent pathway, a possible mechanism for asbestos-induced oncogenesis. Proc Natl Acad Sci. 2006;103(27):10397-402. doi:10.1073/pnas.0604008103.
45. Carbone M, Yang H. Molecular pathways: targeting mechanisms of asbestos and erionite carcinogenesis in mesothelioma. Clin Cancer Res. 2013;18(3):598-604. doi:10.1158/1078-0432.CCR-11-2259.
46. Shukla A, Gulumian M, Hei TK, Kamp D, Rahman Q, Mossman BT. Multiple roles of oxidants in the pathogenesis of asbestos-induced diseases. Free Radic Biol Med. 2003;34(9):1117-29. doi:10.1016/S0891-5849(03)00060-1.
47. Xu A, Zhou H, Yu DZ, Hei TK. Mechanisms of the genotoxicity of crocidolite asbestos in mammalian cells: implication from mutation patterns induced by reactive oxygen species. Environ Health Perspect. 2002;110(10):1003-8.
48. Weiner S, Neragi-Miandoab S. Pathogenesis of malignant pleural mesothelioma and the role of environmental and genetic factors. J Carcinog. 2008;7(1):3.
49. Virta RL. Mineral commodity profiles-asbestos. U.S. Geological Survey, Reston. http://pubs.usgs.gov/circ/2005/1255/kk/ (2005). Accessed 14 Apr 2013.
50. Tweedale G. Asbestos and its lethal legacy. Nat Rev Cancer. 2002;2(4):311-4.
51. Levine AJ, Oren M. The first 30 years of p53: growing ever more complex. Nat Rev Cancer. 2009;9(10):749-58.
52. Linzer DIH, Maltzman W, Levine AJ. The SV40 a gene product is required for the production of a 54,000 MW cellular tumor antigen. Virology. 1979;98(2):308-18. doi:10.1016/0042-6822(79)90554-3.
53. Ben David Y, Prideaux VR, Chow V, Benchimol S, Berstein A. Inactivation of the p53 oncogene by internal deletion or retroviral integration in erythroleukemic cell lines induced by Friend leukemia virus. Oncogene. 1988;3(2):179-85.
54. Wolf D, Rotter V. Inactivation of p53 gene expression by an insertion of Moloney murine leukemia virus-like DNA sequences. Mol Cell Biol. 1984;4(7):1402-10. doi:10.1128/mcb.4.7.1402.
55. Mowat M, Cheng A, Kimura N, Bernstein A, Benchimol S. Rearrangements of the cellular p53 gene in erythroleukaemic cells transformed by Friend virus. Nature. 1985;314(6012):633-6.
56. Vogelstein B, Lane D. Surfing the p53 network. Nature. 2000;408(6810):307.
57. Srivastava S, Zou Z, Pirollo K, Blattner W, Chang EH. Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumeni syndrome. Nature. 1990;348(6303):747-9. doi:10.1038/348747a0.
58. Shaw P, Bovey R, Tardy S, Sahli R, Sordat B, Costa J. Induction of apoptosis by wild-type p53 in a human colon tumor-derived cell line. Proc Natl Acad Sci. 1992;89(10):4495-9.
59. Yonish-Rouach E, Resnftzky D, Lotem J, Sachs L, Kimchi A, Oren M. Wild-type p53 induces apoptosis ofmyeloid leukaemic cells that is inhibited by interleukin-6. Nature. 1991;352(6333):345.
60. Ventura A, Kirsch DG, McLaughlin ME, Tuveson DA, Grimm J, Lintault L, et al. Restoration of p53 function leads to tumour regression in vivo. Nature. 2007;445(7128):661.
61. Xue W, Zender L, Miething C, Dickins RA, Hernando E, Krizhanovsky V, et al. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature. 2007;445(7128):656.
62. Menendez D, Inga A, Resnick MA. The expanding universe of p53 targets. Nat Rev Cancer. 2009;9(10):724-37.
63. Hermeking H. p53 enters the microRNA world. Cancer Cell. 2007;12(5):414-8. doi:10.1016/j.ccr.2007.10.028.
64. Oliner JD, Pietenpol JA, Thiagalingam S, Gyuris J, Kinzler KW, Vogelstein B. Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature. 1993;362(6423):857-60.
65. Chène P. Inhibiting the p53-MDM2 interaction: an important target for cancer therapy. Nat Rev Cancer. 2003;3(2):102.
66. Shangary S, Wang S. Targeting the MDM2-p53 interaction for cancer therapy. Clin Cancer Res. 2008;14(17):5318-24. doi:10.1158/1078-0432.ccr-07- 5136.
67. Peng Z. Current status of gendicine in China: recombinant human Ad-p53 agent for treatment of cancers. Hum Gene Ther. 2005;16(9):16-27.
68. Metcalf RA, Welsh JA, Bennett WP, Seddon MB, Lehman TA, Pelin K, et al. p53 and Kirsten-ras mutations in human mesothelioma cell lines. Cancer Res. 1992;52(9):2610-5.
69. Sekido Y. Molecular pathogenesis of malignant mesothelioma. Carcinogenesis. 2013;34(7):1413-9. doi:10.1093/carcin/bgt166.
70. Vivo C, Lecomte C, Levy F, Leroy K, Kirova Y, Renier A, et al. Cell cycle checkpoint status in human malignant mesothelioma cell lines: response to gamma radiation. Br J Cancer. 2003;88(3):388-95.
71. Murthy SS, Testa JR. Asbestos, chromosomal deletions, and tumor suppressor gene alterations in human malignant mesothelioma. J Cell Physiol. 1999;180(2):150-7. doi:10.1002/(sici)1097-4652(199908)180:2〈150::aid- jcp2〉3.0.co;2-h.
72. Steck PA, Pershouse MA, Jasser SA, Yung WKA, Lin H, Ligon AH, et al. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet. 1997;15(4):356-62.
73. Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science. 1997;275(5308):1943-7.
74. Song MS, Salmena L, Pandolfi PP. The functions and regulation of the PTEN tumour suppressor. Nat Rev Mol Cell Biol. 2012;13(5):283-96.
75. Carracedo A, Alimonti A, Pandolfi PP. PTEN Level in tumor suppression: how much is too little? Cancer Res. 2011;71(3):629-33. doi:10.1158/0008-5472. can-10-2488.
76. Cristofano AD, Pesce B, Cordon-Cardo C, Pandolfi PP. Pten is essential for embryonic development and tumour suppression. Nat Genet. 1998;19(4):348-55. doi:10.1038/1235.
77. Suzuki A, de la Pompa JL, Stambolic V, Elia AJ, Sasaki T, Barrantes IDB. High cancer susceptibility and embryonic lethality associated with mutation of the PTEN tumor suppressor gene in mice. Curr Biol. 1998;8(21):1169-78.
78. Whang YE, Wu X, Suzuki H, Reiter RE, Tran C, Robert L, et al. Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression. Proc Natl Acad Sci. 1998;95(9):5246-50.
79. Lachyankar MB, Sultana N, Schonhoff CM, Mitra P, Poluha W, Lambert S, et al. A role for nuclear PTEN in neuronal differentiation. J Neurosci. 2000;20(4):1404-13.
80. Ginn-Pease ME, Eng C. Increased nuclear phosphatase and tensin homologue deleted on chromosome 10 is associated with G0-G1 in MCF-7 Cells. Cancer Res. 2003;63(2):282-6.
81. Déléris P, Bacqueville D, Gayral SP, Carrez L, Salles J-P, Perret B, et al. SHIP-2 and PTEN are expressed and active in vascular smooth muscle cell nuclei, but only SHIP-2 is associated with nuclear speckles. J Biol Chem. 2003;278(40):38884-91.
82. Trotman LC, Niki M, Dotan ZA, Koutcher JA, Di Cristofano A, Xiao A, et al. Pten dose dictates cancer progression in the prostate. PLoS Biol. 2003;1(3):e59.
83. Meng F, Henson R, Wehbe-Janek H, Ghoshal K, Jacob ST, Patel T. MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology. 2007;133(2):647-58.
84. García JM, Silva J, Peña C, Garcia V, Rodríguez R, Cruz MA, et al. Promoter methylation of the PTEN gene is a common molecular change in breast cancer. Genes Chromosom Cancer. 2004;41(2):117-24. doi:10.1002/gcc.20062.
85. Torres J, Pulido R. The tumor suppressor PTEN is phosphorylated by the protein kinase CK2 at its C terminus: implications for PTEN stability to proteasome-mediated degradation. J Biol Chem. 2001;276(2):993-8. doi:10.1074/jbc.M009134200.
86. 2. J Biol Chem. 2002;277(23):20336-42. doi:10.1074/jbc.M111899200.
87. Leslie NR, Bennett D, Lindsay YE, Stewart H, Gray A, Downes CP. Redox regulation of PI 3-kinase signalling via inactivation of PTEN. EMBO J. 2003;22(20):5501-10.
88. Faivre S, Kroemer G, Raymond E. Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Discov. 2006;5(8):671-88.
89. Borders EB, Bivona C, Medina PJ. Mammalian target of rapamycin: biological function and target for novel anticancer agents. Am J Health Syst Pharm. 2010;67(24):2095-106. doi:10.2146/ajhp100020.
90. Holmes D. PI3K pathway inhibitors approach junction. Nat Rev Drug Discov. 2011;10(8):563-4.
91. van der Heijden MS, Bernards R. Inhibition of the PI3K pathway: hope we can believe in? Clinical Cancer Research. 2010. doi:10.1158/1078-0432.ccr-09- 3004.
92. Shen WH, Balajee AS, Wang J, Wu H, Eng C, Pandolfi PP, et al. Essential role for nuclear PTEN in maintaining chromosomal integrity. Cell. 2007;128(1):157-70.
93. Chung J-H, Ostrowski MC, Romigh T, Minaguchi T, Waite KA, Eng C. The ERK1/2 pathway modulates nuclear PTEN-mediated cell cycle arrest by cyclin D1 transcriptional regulation. Hum Mol Genet. 2006;15(17):2553-9. doi:10.1093/hmg/ddl177.
94. Li AG, Piluso LG, Cai X, Wei G, Sellers WR, Liu X. Mechanistic insights into maintenance of high p53 acetylation by PTEN. Mol Cell. 2006;23(4):575-87.
95. Mayo LD, Dixon JE, Durden DL, Tonks NK, Donner DB. PTEN protects p53 from Mdm2 and sensitizes cancer cells to chemotherapy. J Biol Chem. 2002;277(7):5484-9. doi:10.1074/jbc.M108302200.
96. Mayo LD, Donner DB. A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of MDM2 from the cytoplasm to the nucleus. Proc Natl Acad Sci. 2001;98(20):11598-603. doi:10.1073/pnas.181181198.
97. Berger AH, Knudson AG, Pandolfi PP. A continuum model for tumour suppression. Nature. 2011;476(7359):163-9.
98. Alimonti A, Nardella C, Chen Z, Clohessy JG, Carracedo A, Trotman LC, et al. A novel type of cellular senescence that can be enhanced inmousemodels and human tumor xenografts to suppress prostate tumorigenesis. J Clin Invest. 2010;120(3):681-93. doi:10.1172/jci40535.
99. Nardella C, Clohessy JG, Alimonti A, Pandolfi PP. Pro-senescence therapy for cancer treatment. Nat Rev Cancer. 2011;11(7):503-11. doi:10.1038/nrc3057.
100. Tanaka M, Rosser CJ, Grossman HB. PTEN gene therapy induces growth inhibition and increases efficacy of chemotherapy in prostate cancer. Cancer Detect Prev. 2005;29(2):170-4.
101. Saito Y, Swanson X, Mhashilkar AM, Oida Y, Schrock R, Branch CD, et al. Adenovirus-mediated transfer of the PTEN gene inhibits human colorectal cancer growth in vitro and in vivo. Gene Ther. 2003;10(23):1961-9.
102. Garland LL, Rankin C, Gandara DR, Rivkin SE, Scott KM, Nagle RB, et al. Phase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest Oncology Group study. J Clin Oncol. 2007;25(17):2406-13. doi:10.1200/jco.2006.09.7634.
103. Knudson AJ. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci. 1971;68(4):820-3.
104. Fung YK, Murphree AL, T'Ang A, Qian J, Hinrichs SH, Benedict WF. Structural evidence for the authenticity of the human retinoblastoma gene. Science. 1987;236(4809):1657-61.
105. Venkatachalam S, Shi Y-P, Jones SN, Vogel H, Bradley A, Pinkel D, et al. Retention of wild-type p53 in tumors from p53 heterozygous mice: reduction of p53 dosage can promote cancer formation. EMBO J. 1998;17(16):4657-67.
106. Varley JM, Evans DG, Birch JM. Li-Fraumeni syndrome - a molecular and clinical review. Br J Cancer. 1997;1997(76):1-14.
107. Alimonti A, Carracedo A, Clohessy JG, Trotman LC, Nardella C, Egia A, et al. Subtle variations in Pten dose determine cancer susceptibility. Nat Genet. 2010;42(5):454-8.
108. Rusch VW, Venkatraman E. The importance of surgical staging in the treatment of malignant pleural mesothelioma. J Thorac Cardiovasc Surg. 1996;111(4):815-26.
109. Bölükbasa S, Manegold C, Eberlein M, Bergmann T, Fisseler-Eckhoff A, Schirren J. Survival after trimodality therapy for malignant pleuralmesothelioma: radical pleurectomy, chemotherapy with cisplatin/pemetrexed and radiotherapy. Lung Cancer. 2011;71(1):75-81. doi:10.1016/j.lungcan.2009.08.019.
110. Treasure T, Sedrakyan A. Pleural mesothelioma: little evidence, still time to do trials. Lancet. 2004;364(9440):1183-5. doi:10.1016/S0140-6736(04) 17108-0.
111. Bissett D, Macbeth FR, Cram I. The role of palliative radiotherapy in malignant mesothelioma. Clin Oncol. 1991;3(6):315-7. doi:10.1016/S0936-6555(05) 80582-5.
112. Hazarika M, White Jr RM, Booth BP, Wang YC, Ham DY, Liang CY, et al. Pemetrexed in malignant pleural mesothelioma. Clin Cancer Res. 2005;11(3):982.
113. Berghmans T, Paesmans M, Lalami Y, Louviaux I, Luce S, Mascaux C. Activity of chemotherapy and immunotherapy on malignant mesothelioma: a systematic review of the literature with meta-analysis. Lung Cancer. 2002;38(2):111-21 (Amsterdam, Netherlands).
114. Fizazi K, Ducreux M, Ruffié P, Bonnay M, Daniel C, Soria J-C, et al. Phase I, dose-finding, and pharmacokinetic study of raltitrexed combined with oxaliplatin in patients with advanced cancer. J Clin Oncol. 2000;18(11):2293-300.
115. Fizazi K, Doubre H, Le Chevalier T, Riviere A, Viala J, Daniel C, et al. Combination of raltitrexed and oxaliplatin is an active regimen in malignantmesothelioma: results of a phase II study. J Clin Oncol. 2003;21(2):349-54. doi:10.1200/jco.2003.05.123.
116. Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003;21(14):2636-44. doi:10.1200/jco.2003.11.136.
117. Karrison T, Kindler HL, Gandara DR, Lu C, Guterz TL, Nichols K, et al. Final analysis of a multi-center, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin (GC) plus bevacizumab (B) or placebo (P) in patients (pts) with malignant mesothelioma (MM). J Clin Oncol. 2007;25(18):5. (Suppl 18S Abstract 7526):391s.
118. Jänne PA, Taffaro ML, Salgia R, Johnson BE. Inhibition of epidermal growth factor receptor signaling in malignant pleural mesothelioma. Cancer Res. 2002;62(18):5242-7.
119. Govindan R, Kratzke RA, Herndon JE, Niehans GA, Vollmer R, Watson D, et al. Gefitinib in patients with malignant mesothelioma: a phase II study by the cancer and leukemia group B. Clin Cancer Res. 2005;11(6):2300-4. doi:10.1158/1078-0432.ccr-04-1940.
120. Jackman DM, Kindler HL, Yeap BY, Fidias P, Salgia R, Lucca J, et al. Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma. Cancer. 2008;113(4):808-14. doi:10.1002/cncr.23617.
121. Rvd M, Robinson B, Nelson D. Gene therapy for malignant mesothelioma: beyond the infant years. Cancer Gene Ther. 2006;13(10):897-904.
122. Lindsay Y, McCoull D, Davidson L, Leslie NR, Fairservice A, Gray A, et al. Localization of agonist-sensitive PtdIns(3,4,5)P3 reveals a nuclear pool that is insensitive to PTEN expression. J Cell Sci. 2006;119(24):5160-8. doi:10.1242/jcs.000133.